| UniProt ID | SC65_HUMAN | |
|---|---|---|
| UniProt AC | Q92791 | |
| Protein Name | Endoplasmic reticulum protein SC65 {ECO:0000303|PubMed:23959653} | |
| Gene Name | P3H4 {ECO:0000312|HGNC:HGNC:16946} | |
| Organism | Homo sapiens (Human). | |
| Sequence Length | 437 | |
| Subcellular Localization | Endoplasmic reticulum . | |
| Protein Description | Part of a complex composed of PLOD1, P3H3 and P3H4 that catalyzes hydroxylation of lysine residues in collagen alpha chains and is required for normal assembly and cross-linking of collagen fibrils. Required for normal bone density and normal skin stability via its role in hydroxylation of lysine residues in collagen alpha chains and in collagen fibril assembly.. | |
| Protein Sequence | MARVAWGLLWLLLGSAGAQYEKYSFRGFPPEDLMPLAAAYGHALEQYEGESWRESARYLEAALRLHRLLRDSEAFCHANCSGPAPAAKPDPDGGRADEWACELRLFGRVLERAACLRRCKRTLPAFQVPYPPRQLLRDFQSRLPYQYLHYALFKANRLEKAVAAAYTFLQRNPKHELTAKYLNYYQGMLDVADESLTDLEAQPYEAVFLRAVKLYNSGDFRSSTEDMERALSEYLAVFARCLAGCEGAHEQVDFKDFYPAIADLFAESLQCKVDCEANLTPNVGGYFVDKFVATMYHYLQFAYYKLNDVRQAARSAASYMLFDPKDSVMQQNLVYYRFHRARWGLEEEDFQPREEAMLYHNQTAELRELLEFTHMYLQSDDEMELEETEPPLEPEDALSDAEFEGEGDYEEGMYADWWQEPDAKGDEAEAEPEPELA | |
| Overview of Protein Modification Sites with Functional and Structural Information | ||
|
|
||
* ASA = Accessible Surface Area
| Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
|---|---|---|---|---|---|
| 20 | Phosphorylation | LGSAGAQYEKYSFRG HHHCCCHHHCCCCCC | 17.54 | - | |
| 23 | Phosphorylation | AGAQYEKYSFRGFPP CCCHHHCCCCCCCCH | 10.91 | - | |
| 88 | Ubiquitination | SGPAPAAKPDPDGGR CCCCCCCCCCCCCCC | 52.65 | 21963094 | |
| 160 | Ubiquitination | FKANRLEKAVAAAYT HHHHHHHHHHHHHHH | 53.40 | 29967540 | |
| 174 | Ubiquitination | TFLQRNPKHELTAKY HHHHHCCCHHHHHHH | 53.94 | 29967540 | |
| 186 | Ubiquitination | AKYLNYYQGMLDVAD HHHHHHHHHHHHHCC | 22.06 | 21963094 | |
| 213 | Ubiquitination | AVFLRAVKLYNSGDF HHHHHHHHHHCCCCC | 44.24 | 33845483 | |
| 234 | Phosphorylation | MERALSEYLAVFARC HHHHHHHHHHHHHHH | 9.15 | 17053785 | |
| 315 | Phosphorylation | DVRQAARSAASYMLF HHHHHHHHHHHHHHC | 24.38 | 24247654 | |
| 325 | Ubiquitination | SYMLFDPKDSVMQQN HHHHCCCCCCHHHHC | 65.56 | 21963094 | |
| 335 | Phosphorylation | VMQQNLVYYRFHRAR HHHHCHHHHHHHHHH | 7.65 | 24247654 | |
| 361 | N-linked_Glycosylation | EEAMLYHNQTAELRE HHHHHHCCCHHHHHH | 27.60 | - | |
| 423 | Ubiquitination | DWWQEPDAKGDEAEA CCCCCCCCCCCCCCC | 28.57 | 21963094 |
| Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
|---|---|---|---|---|---|---|
Oops, there are no upstream regulatory protein records of SC65_HUMAN !! | ||||||
| Modified Location | Modified Residue | Modification | Function | Reference | ||
|---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of SC65_HUMAN !! | ||||||
* Distance = the distance between SAP position and PTM sites.
| Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
|---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of SC65_HUMAN !! | ||||||
| Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
|---|---|---|---|---|
Oops, there are no PPI records of SC65_HUMAN !! | ||||
| Kegg Disease | ||||||
|---|---|---|---|---|---|---|
| There are no disease associations of PTM sites. | ||||||
| OMIM Disease | ||||||
| There are no disease associations of PTM sites. | ||||||
| Kegg Drug | ||||||
| There are no disease associations of PTM sites. | ||||||
| DrugBank | ||||||
| There are no disease associations of PTM sites. | ||||||
loading...
| Phosphorylation | |
| Reference | PubMed |
| "Tyrosine phosphorylated Par3 regulates epithelial tight junctionassembly promoted by EGFR signaling."; Wang Y., Du D., Fang L., Yang G., Zhang C., Zeng R., Ullrich A.,Lottspeich F., Chen Z.; EMBO J. 25:5058-5070(2006). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-234, AND MASSSPECTROMETRY. | |